phrykt

Prelude Therapeutics Inc (PRLD): who owns it and who trades it

As of Nov 16, 2026, PRLD insiders reported 2 purchases worth $12.5M in the last 12 months. The largest buyer was David P Bonita (Director), with $12.5M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Prelude Therapeutics

From the latest filings

Overall: more buying than selling. Funds, insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns PRLD

76 funds and institutions reported PRLD shares worth $265M at the end of Q2 2026, about 79% of the company. The largest holder is Orbimed Advisors LLC with 21.8%.

Funds and institutions (13F) 79%Everyone else 21%

10 largest owners, by share of the company

Orbimed Advisors LLC21.8%
Baker Bros. Advisors LP16.1%
Ra Capital Management, L.P.10.3%
Soleus Capital Management, L.P.5.4%
Kynam Capital Management, LP3.8%
Vanguard Capital Management LLC3.2%
BlackRock, Inc.2.9%
Sphera Funds Management Ltd.1.6%
Two Sigma Investments, LP1.6%
ADAR1 Capital Management, LLC1.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Orbimed Advisors LLC13.72M21.78%$73.2M+26%
Baker Bros. Advisors LP10.12M16.07%$54MNo change
Ra Capital Management, L.P.6.48M10.28%$34.5MNew
Soleus Capital Management, L.P.3.38M5.36%$18MNew
Kynam Capital Management, LP2.42M3.83%$12.9M+52%
Vanguard Capital Management LLC2.01M3.19%$10.7M+63%
BlackRock, Inc.1.80M2.85%$9.6M+458%
Sphera Funds Management Ltd.1.02M1.62%$5.4M+83%
Two Sigma Investments, LP993,3691.58%$5.3M+8%
ADAR1 Capital Management, LLC900,9001.43%$4.8M+489%
Millennium Management LLC844,9931.34%$4.5M+121%
Geode Capital Management, LLC841,8621.34%$4.5M+178%
Adage Capital Partners Gp, L.l.c.766,0951.22%$4.1MNew
Acadian Asset Management LLC611,3590.97%$3.3M+20%
Morgan Stanley503,8600.80%$2.7M+56%
State Street Corp428,7870.68%$2.3M+210%
UBS Group AG318,7970.51%$1.7M+394%
Vanguard Fiduciary Trust Co284,8860.45%$1.5M+81%
Renaissance Technologies LLC281,2000.45%$1.5M+2%
Northern Trust Corp240,5990.38%$1.3M+380%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, PRLD insiders reported $12.5M of open-market purchases and $0 of sales.

Purchases, 12 months
$12.5M
2 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Apr 21, 2026
Filed Apr 23, 2026

Purchases and sales by month

$12.5M$12.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Apr 21, 2026David P BonitaDirectorPurchase1.69M$4.44$7.5MForm 4
Apr 21, 2026David P BonitaDirectorPurchase1.13M$4.44$5MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
David P BonitaDirector, 10% owner$12.5M–Apr 21, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PRLD short interest

Moderate short interest. 5.2% of PRLD shares are sold short: about 1 share in 19. Over the last 12 reports the number of shares short went up 126%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.18M PRLD shares were sold short, 5.2% of the shares outstanding, down 18.0% from the report before. At the average daily volume of 456,823 shares, buying them all back would take about 9.1 trading days (days to cover).

Shares short, % of all shares

5.23%May 15Oct 306.94%

Days to cover

9.1May 15Oct 3012.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.18M5.23%-18%456,8239.1
Oct 15, 20265.10M6.39%+11%444,22411.5
Sep 30, 20264.58M5.73%+26%578,2157.9
Sep 15, 20263.63M4.54%+1%402,8939.0
Aug 31, 20263.59M4.50%-6%643,3025.6
Aug 14, 20263.82M4.78%+4%391,3819.8
Jul 31, 20263.67M5.83%+12%394,2229.3
Jul 15, 20263.29M5.22%+16%344,5459.5
Jun 30, 20262.82M4.48%+57%812,1433.5
Jun 15, 20261.79M2.85%+6%285,5136.3
May 29, 20261.69M2.69%-9%315,0045.4
May 15, 20261.85M2.94%+19%522,8743.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Prelude Therapeutics company events

Prelude Therapeutics filed 11 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Sep 10, 2026.

  1. Sep 10, 2026AnnouncementShared information with investors. Filing
  2. Aug 11, 2026ResultsReleased financial results. Filing
  3. Jun 10, 2026VoteReported shareholder vote results. Filing
  4. May 12, 2026ResultsReleased financial results. Filing
  5. Apr 21, 2026AgreementPrelude Therapeutics Incorporated entered into an underwriting agreement with Goldman Sachs & Co. LLC and Evercore Group L.L.C. as representatives of the underwriters named therein, pursuant to which Prelude agreed to issue and sell an aggregate of (a) 18,018,014 shares of its voting common stock… Filing
  6. Apr 20, 2026AnnouncementThe Company will present preclinical data from its lead development candidate, PRT 13722, at the AACR Annual Meeting 2026 on April 20, 2026. Filing
  7. Apr 15, 2026LeadershipOn April 15, 2026 Prelude Therapeutics Incorporated, announced that the Board of Directors of the Company appointed Charles Q. Morris, M.D., age 61, as the Chief Medical Officer of the Company, effective on April 20, 2026. Filing
  8. Mar 12, 2026AnnouncementAs previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 15, 2023, Prelude Therapeutics Incorporated entered into an Open Market Sale Agreement SM with Jefferies LLC, as sales agent, relating to shares of the Company’s common stock, par… Filing
  9. Mar 10, 2026ResultsReleased financial results. Filing
  10. Feb 3, 2026AnnouncementShared information with investors. Filing
  11. Jan 9, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Prelude Therapeutics financials

Famous investors that hold PRLD

3 of the 50 well-known investors we track reported holding PRLD in their latest 13F filing. The largest position is Israel Englander's, worth $1.8M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026466,766$1.8M0.0%-45%
Jim Simons · Renaissance TechnologiesQ3 2026297,709$1.2M0.0%+6%
Ken Griffin · Citadel AdvisorsQ3 2026212,903$832K0.0%+844%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Prelude Therapeutics Inc (PRLD) stock

Who owns the most PRLD stock?

The largest reported owner of Prelude Therapeutics Inc (PRLD) is Orbimed Advisors LLC, with 21.8% of the company. In total, 76 funds and institutions reported holding PRLD at the end of Q2 2026, together about 79% of the shares. See the largest owners.

Are PRLD insiders buying or selling?

In the last 12 months, PRLD insiders reported 2 open-market purchases worth $12.5M and no sales. The latest trade was on Apr 21, 2026. See every trade.

What is the short interest in PRLD?

As of Oct 30, 2026, 4.18M PRLD shares were sold short, 5.2% of the shares outstanding, down 18.0% from the report before. At the average daily volume of 456,823 shares, buying them all back would take about 9.1 trading days (days to cover). See the history.

Which famous investors hold PRLD?

3 of the 50 well-known investors we track reported PRLD in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $1.8M. See all holders.

Executive pay

Prelude Therapeutics's chief executive was paid a total of $1.3M for the year ended Dec 31, 2025, down 42% from $2.3M the year before. In the last 12 months, Prelude Therapeutics's executives and directors bought $12.5M of stock on the open market and sold none.

Chief executive, total pay$1.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$2.4MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$834KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.